Board appointment

Vectura's Chief Operations Officer appointed to the Board

Chippenham, UK - 3 May 2012: Vectura Group plc (LSE: VEC) ("Vectura"), which specialises in developing therapies, principally for the treatment of respiratory diseases, announces that Dr Trevor Phillips, BSc PhD MBA, will join the Board with effect from 1 June 2012.

Trevor Phillips, aged 51, was appointed Chief Operations Officer in July 2011, having joined Vectura in January 2010 as President of US Operations. Prior to joining Vectura he gained extensive international experience in organisational leadership, management and pharmaceutical drug development in a number of senior roles, including positions as CEO and President of the US publicly held company, Critical Therapeutics Inc, following six years as the Company's Chief Operating Officer. During his time at Critical Therapeutics, Trevor was involved in establishing commercial partnerships, product in-licensing and out-licensing, managing drug development and NDA filings, commercial product manufacturing, and mergers and acquisitions.

Between 1986 and 2002, Trevor held a number of management positions including at Sepracor, Accenture and GlaxoWellcome. Trevor trained as a microbiologist at University of Reading, obtaining a PhD in microbial biochemistry from the University of Wales in 1986. He was awarded an MBA from Henley Management College in 1997.

Jack Cashman, Chairman of Vectura:

"We welcome Trevor's addition to the Board where his extensive industry experience in both European and US public listed pharmaceutical companies will be an asset to us as we evolve on the next stage of growth, positioning ourselves as a key player in the respiratory market.

There are no other matters requiring disclosure in respect of Dr Phillips' appointment under Listing Rule 9.6.13 of the Listing Rules of the UK Listing Authority.

- Ends -

Enquiries

Notes for editors

About Vectura

Vectura Group plc develops inhaled therapies principally for the treatment of respiratory diseases. Vectura's main products target diseases such as asthma and chronic obstructive pulmonary disease (COPD), a growing market that is currently estimated to be worth in excess of $25bn.

Vectura has six products marketed by its partners and a portfolio of drugs in clinical and pre-clinical development, a number of which have been licensed to major pharmaceutical companies. Vectura has development collaborations and licence agreements with several pharmaceutical companies, including Novartis, Sandoz (the generics arm of Novartis), Baxter and GlaxoSmithKline (GSK).

Vectura seeks to develop certain programmes itself where this will optimise value. Vectura's formulation and inhalation technologies are available to other pharmaceutical companies on an out-licensing basis where this complements Vectura's business strategy. For further information, please visit Vectura's website at www.vectura.com

Forward-looking statements

This press release contains forward-looking statements, including statements about the discovery, development and commercialisation of products. Various risks may cause Vectura's actual results to differ materially from those expressed or implied by the forward-looking statements, including: adverse results in clinical development programmes; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialise products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialisation activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.